Nexalin Issuance Of Capital Stock from 2010 to 2024

NXL Stock  USD 4.22  0.24  6.03%   
Nexalin Technology Issuance Of Capital Stock yearly trend continues to be quite stable with very little volatility. The value of Issuance Of Capital Stock is projected to decrease to 0.00. From the period between 2010 and 2024, Nexalin Technology, Issuance Of Capital Stock regression line of its data series had standard deviation of  2,031,747 and standard deviation of  2,031,747. View All Fundamentals
 
Issuance Of Capital Stock  
First Reported
2010-12-31
Previous Quarter
0.0
Current Value
0.0
Quarterly Volatility
M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Nexalin Technology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Nexalin Technology's main balance sheet or income statement drivers, such as Depreciation And Amortization of 2.5 K, Interest Expense of 54.4 K or Selling General Administrative of 4 M, as well as many indicators such as Price To Sales Ratio of 25.55, Dividend Yield of 0.0 or PTB Ratio of 0.98. Nexalin financial statements analysis is a perfect complement when working with Nexalin Technology Valuation or Volatility modules.
  
Check out the analysis of Nexalin Technology Correlation against competitors.
For more information on how to buy Nexalin Stock please use our How to buy in Nexalin Stock guide.

Latest Nexalin Technology's Issuance Of Capital Stock Growth Pattern

Below is the plot of the Issuance Of Capital Stock of Nexalin Technology over the last few years. It is Nexalin Technology's Issuance Of Capital Stock historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Nexalin Technology's overall financial position and show how it may be relating to other accounts over time.
Issuance Of Capital Stock10 Years Trend
Pretty Stable
   Issuance Of Capital Stock   
       Timeline  

Nexalin Issuance Of Capital Stock Regression Statistics

Arithmetic Mean1,313,596
Geometric Mean0.00
Coefficient Of Variation154.67
Mean Deviation980,246
Median884,082
Standard Deviation2,031,747
Sample Variance4.1T
Range8.5M
R-Value0.23
Mean Square Error4.2T
R-Squared0.05
Significance0.41
Slope103,613
Total Sum of Squares57.8T

Nexalin Issuance Of Capital Stock History

2023null
20228.5 M
20211.4 M

About Nexalin Technology Financial Statements

Nexalin Technology investors utilize fundamental indicators, such as Issuance Of Capital Stock, to predict how Nexalin Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Nexalin Technology is a strong investment it is important to analyze Nexalin Technology's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Nexalin Technology's future performance. For an informed investment choice regarding Nexalin Stock, refer to the following important reports:
Check out the analysis of Nexalin Technology Correlation against competitors.
For more information on how to buy Nexalin Stock please use our How to buy in Nexalin Stock guide.
You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Nexalin Technology. If investors know Nexalin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Nexalin Technology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.65)
Revenue Per Share
0.02
Quarterly Revenue Growth
(0.24)
Return On Assets
(1.19)
Return On Equity
(2.02)
The market value of Nexalin Technology is measured differently than its book value, which is the value of Nexalin that is recorded on the company's balance sheet. Investors also form their own opinion of Nexalin Technology's value that differs from its market value or its book value, called intrinsic value, which is Nexalin Technology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Nexalin Technology's market value can be influenced by many factors that don't directly affect Nexalin Technology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Nexalin Technology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Nexalin Technology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Nexalin Technology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.